Home / Explore Insights / Applied Clinical Trials Features Marina Acosta Enslen’s Thoughts on Covid-19 Forcing Companies to Comply with the New E6 (R2) Guidelines
/ News & Media / Recent News / Applied Clinical Trials Features Marina Acosta Enslens Thoughts On Covid 19 Forcing Companies To Comply With The New E6 R2 Guidelines
Applied Clinical Trials Features Marina Acosta Enslen’s Thoughts on Covid-19 Forcing Companies to Comply with the New E6 (R2) Guidelines
In the December issue of Applied Clinical Trials, Marina Acosta Enslen weighs in on how COVID-19 has forced compliancy within organizations following the implementation of E6 (R2). Read the full article here (page 24).